Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more
Inogen, which manufactures portable oxygen concentrators, raised $71 million by offering 4.4 million shares at $16, the low end of the range of $16 to $18. Inogen plans to list on the NASDAQ under the symbol INGN. Inogen initially filed confidentially on...read more
Much has been written about the recent explosion of biotech IPOs, and last week they accounted for seven of the ten IPOs that priced. Together, they had an average deal size of less than $70 million, and averaged a 16% return. Revance (RVNC), a biotech...read more
US IPO Recap: Wave goodbye to the biotech wave as tech prepares to take over
Last week marked the end of the greatest amount of biotech activity across a two-week stretch in over a decade (14 pricings from 1/29 to 2/11). However, without any superstar performers like January’s Dicerna (DRNA; up 160%) or Ultragenyx (RARE; 110%),...read more
Inogen prices IPO at $16, the low end of the range
Inogen, which manufactures portable oxygen concentrators, raised $71 million by offering 4.4 million shares at $16, the low end of the range of $16 to $18. Inogen plans to list on the NASDAQ under the symbol INGN. Inogen initially filed confidentially on...read more
9 US IPOs planned for the week of Feb 10
The following IPOs are expected to price this week: Amedica (AMDA), which develops and sells medical devices using its silicon nitride technology platform, plans to...read more
US IPO Recap: Revance jumps 68% in ten-IPO week
Much has been written about the recent explosion of biotech IPOs, and last week they accounted for seven of the ten IPOs that priced. Together, they had an average deal size of less than $70 million, and averaged a 16% return. Revance (RVNC), a biotech...read more